FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlaxoSmithKline

SPOTLIGHT: GSK's Arixtra losing to Rivaroxaban

Tools


A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, the report cites Arixtra's need for close monitoring and its potential for serious side effects such as hemorrhage. Article

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Comments (2) | Post a comment
More stories about GlaxoSmithKline  

Comments

Good one

That's amazing given that rivaroxaban hasn't been launched yet. Regarding hemorrrage and close monitoring, things that are not associated with Arixtra, maybe there is some confusion with warfarin...? What utter rubbish!

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.